Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when STRO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSutro Biopharma reports Q1 2026 financial results
Filed May 14, 2026 · Period ending May 14, 2026 · ~1 min read
Key Changes
-
medium
Sutro Biopharma announced Q1 2026 financial results for the quarter ended March 31, 2026 via press release. The 8-K references the attached press release but does not include specific financial metrics in the filing body.
Item 2.02 verify on EDGAR →
Summary
Sutro Biopharma filed an 8-K on May 14, 2026 to announce its first quarter 2026 financial results. The filing is a standard quarterly earnings disclosure, with the actual financial metrics and operational updates contained in an attached press release rather than in the 8-K body itself. This is routine practice for public companies reporting quarterly performance.
For retail investors, the key information will be in the press release exhibit, which typically includes revenue, expenses, cash position, and pipeline updates. Investors should review the full press release to understand the company's financial health and progress on its drug development programs. Watch for any guidance updates or changes to clinical trial timelines that may affect the company's near-term prospects.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 14, 2026, Sutro Biopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.
The company disclosed its first quarter 2026 financial results through a press release. The actual financial metrics and performance details are contained in the attached press release exhibit, which is not included in this 8-K body text.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Press release issued by Sutro Biopharma, Inc. regarding its financial results for the quarter ended March 31, 2026, dated May 14, 2026.
The company disclosed its financial results for the first quarter ended March 31, 2026 via press release. The 8-K itself contains no financial details; it simply references the attached press release as Exhibit 99.1.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify